Citigroup Inc. Has $17.66 Million Stake in Smith & Nephew SNATS, Inc. $SNN

Citigroup Inc. raised its position in Smith & Nephew SNATS, Inc. (NYSE:SNN) by 44.8% in the third quarter, HoldingsChannel.com reports. The fund owned 486,661 shares of the medical equipment provider’s stock after purchasing an additional 150,517 shares during the quarter. Citigroup Inc.’s holdings in Smith & Nephew SNATS were worth $17,661,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently modified their holdings of SNN. Royal Bank of Canada raised its holdings in shares of Smith & Nephew SNATS by 16.7% in the 1st quarter. Royal Bank of Canada now owns 340,428 shares of the medical equipment provider’s stock valued at $9,657,000 after purchasing an additional 48,784 shares during the period. Goldman Sachs Group Inc. increased its position in Smith & Nephew SNATS by 49.2% during the first quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider’s stock worth $50,255,000 after buying an additional 583,809 shares during the last quarter. Focus Partners Wealth raised its stake in Smith & Nephew SNATS by 59.8% in the first quarter. Focus Partners Wealth now owns 19,438 shares of the medical equipment provider’s stock valued at $552,000 after buying an additional 7,277 shares during the period. Bessemer Group Inc. raised its stake in Smith & Nephew SNATS by 111.9% in the second quarter. Bessemer Group Inc. now owns 3,709 shares of the medical equipment provider’s stock valued at $114,000 after buying an additional 1,959 shares during the period. Finally, Hantz Financial Services Inc. lifted its position in shares of Smith & Nephew SNATS by 8.3% in the second quarter. Hantz Financial Services Inc. now owns 74,380 shares of the medical equipment provider’s stock valued at $2,278,000 after buying an additional 5,676 shares during the last quarter. Institutional investors own 25.64% of the company’s stock.

Smith & Nephew SNATS Trading Up 0.7%

Shares of Smith & Nephew SNATS stock opened at $36.94 on Friday. The company has a current ratio of 3.00, a quick ratio of 1.40 and a debt-to-equity ratio of 0.60. Smith & Nephew SNATS, Inc. has a twelve month low of $23.91 and a twelve month high of $38.79. The company has a 50-day simple moving average of $34.16 and a two-hundred day simple moving average of $34.97.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on SNN shares. Weiss Ratings reissued a “hold (c+)” rating on shares of Smith & Nephew SNATS in a report on Wednesday, January 21st. Royal Bank Of Canada downgraded shares of Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a report on Monday, December 15th. Kepler Capital Markets upgraded shares of Smith & Nephew SNATS to a “strong-buy” rating in a research note on Monday, November 17th. Wall Street Zen downgraded shares of Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. Finally, Canaccord Genuity Group lowered their price target on shares of Smith & Nephew SNATS from $36.00 to $34.00 and set a “hold” rating on the stock in a report on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $35.75.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.